Perioperative Considerations for Patients Treated with Bleomycin (1)

In: Bleomycin

3 Apr 2013

Perioperative Considerations for Patients Treated with Bleomycin (1)Bleomycin, an antitumor antibiotic produced by Streptomyces verticillus, is a chemotherapeutic agent commonly used in the treatment of germ cell tumors of the testes, lymphomas, and squamous cell carcinomas of the head and neck. Bleomycin has been very effective in the treatment of these malignancies, but its use is limited by its potentially life-threatening pulmonary toxicity. The reported incidence of pulmonary toxicity ranges from 0 to 40 percent of all patients who receive the drug. This wide range is, in part, due to the definition of pulmonary toxicity employed. It is estimated that 11 to 30 percent of all patients who receive bleomycin have nonlethal pulmonary fibrosis. The mortality associated with bleomycin-induced pulmonary toxicity is reported to be 2 to 10 percent of affected patients.

There are reports of ARDS developing in patients who have received bleomycin and have subsequently undergone general anesthesia.” The onset of respiratory failure is usually three to ten days after surgery and is rapidly fatal in most reported cases. buy cheap antibiotics
The number of patients who have received bleomycin is significant. Testicular malignancies alone account for approximately 5,700 new cases of cancer diagnosed each year in the United States; approximately 1,800 of these patients will receive bleomycin.

About this blog

Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.


Buen trato. #photooftheday #photography #medicine #journalism #cdmx
Shanghai, China Conference
Use Ultram To Achieve An Effective Comfort From Painful Condition
Dr Vose Physician  albany ny 1854